Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Responder variables, weeks 18 and 26 (per-protocol set)

From: Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz

Visit (week) Artz Durolane Odds ratio (95%CI)
(5 × 2.5 ml) (1 × 3 ml, 4 × sham)
  ( n= 158) ( n= 161) P value
OMERACT-OARSI
Week 18    
 Responder 146 (92.4%) 152 (94.4%) 1.15 (0.63; 2.09)
 Nonresponder 12 (7.6%) 9 (5.6%) 0.6487
Week 26    
 Responder 148 (93.7%) 151 (93.8%) 1.12 (0.61; 2.05)
 Nonresponder 10 (6.3%) 10 (6.2%) 0.7129
WOMAC pain subscale
Week 18    
 Responder 116 (73.4%) 124 (77.0%) 0.91 (0.62; 1.35)
 Nonresponder 42 (26.6%) 37 (23.0%) 0.6473
Week 26    
 Responder 129 (81.6%) 127 (78.9%) 0.96 (0.65; 1.41)
 Nonresponder 29 (18.4%) 34 (21.1%) 0.8157
WOMAC pain ‘walking on a flat surface’ item
Week 18    
 Responder 152 (96.2%) 149 (92.5%) 2.12 (1.14; 3.94)
 Nonresponder 6 (3.8%) 12 (7.5%) 0.0176
Week 26    
 Responder 153 (96.8%) 148 (91.9%) 2.26 (1.23; 4.12)
 Nonresponder 5 (3.2%) 13 (8.1%) 0.0082
  1. Data presented as n (%). Odds ratio obtained from a generalized estimable equation model. Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). CI, confidence interval; OMERACT-OARSI, Outcome Measures in Rheumatoid Arthritis Clinical Trials – Osteoarthritis Research Society International; WOMAC, Western Ontario and McMaster University.